These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22260987)

  • 21. MenB candidate vaccine Bexsero induces robust immune response in infants.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Mar; 8(3):282. PubMed ID: 23213659
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outer-membrane-vesicle vaccines: old but not forgotten.
    Stephens DS
    Lancet Infect Dis; 2011 Jun; 11(6):421-2. PubMed ID: 21489883
    [No Abstract]   [Full Text] [Related]  

  • 25. The yin and yang of fever after meningococcal B vaccination.
    Ladhani SN; Riordan A
    Arch Dis Child; 2017 Oct; 102(10):881-882. PubMed ID: 28931534
    [No Abstract]   [Full Text] [Related]  

  • 26. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Introducing a new group B meningococcus vaccine.
    Isaacs D; McVernon J
    BMJ; 2014 Apr; 348():g2415. PubMed ID: 24696308
    [No Abstract]   [Full Text] [Related]  

  • 28. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evaluation of MenB vaccines: prerequisites for clinical development.
    Sanders H; Kaaijk P; van den Dobbelsteen GP
    Expert Rev Vaccines; 2013 Jan; 12(1):31-42. PubMed ID: 23256737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines targeting serogroup B meningococci.
    Taha MK; Deghmane AE
    Lancet Infect Dis; 2012 Aug; 12(8):578-9. PubMed ID: 22569483
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines.
    Oviedo-Orta E; Ahmed S; Rappuoli R; Black S
    Vaccine; 2015 Jul; 33(31):3628-35. PubMed ID: 26093201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quest for a broad-range vaccine against Neisseria meningitidis serogroup B: implications of genetic variations of the surface-exposed proteins.
    de Filippis I
    J Med Microbiol; 2009 Sep; 58(Pt 9):1127-1132. PubMed ID: 19528146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A vaccine for meningococcal B disease and gonorrhoea.
    Kirby T
    Lancet Infect Dis; 2020 Apr; 20(4):417. PubMed ID: 32222210
    [No Abstract]   [Full Text] [Related]  

  • 34. Neisseria meningitidis serogroup B: laboratory correlates of protection.
    Vermont C; van den Dobbelsteen G
    FEMS Immunol Med Microbiol; 2002 Oct; 34(2):89-96. PubMed ID: 12381458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact.
    Wassil J; Huels J; Narasimhan V
    Vaccine; 2014 May; 32(25):2943. PubMed ID: 23962533
    [No Abstract]   [Full Text] [Related]  

  • 36. Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.
    Brendish NJ; Read RC
    Expert Rev Vaccines; 2015 Apr; 14(4):493-503. PubMed ID: 25703792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The challenge of post-implementation surveillance for novel meningococcal vaccines.
    Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6835; author reply 6835-6. PubMed ID: 17875437
    [No Abstract]   [Full Text] [Related]  

  • 39. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.